EUCTR2022-000049-34-BG招募中1 期
A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Male or female, 18 to 60 years (inclusive) of age, at the time of signing the informed consent.
- •- Participants with diagnosis of RRMS, SPMS (relapsing or non-relapsing) or primary progressive subtype according to the 2017 revision of the McDonald diagnostic criteria (SPMS diagnostic criteria according to initial relapsing remitting disease course followed by progression with or without occasional relapses, minor remissions, and plateaus; progression denotes the continuous worsening of neurological impairment over at least 6 months).
- •- Participants with Expanded Disability Status Scale (EDSS) score of 2-6 inclusive at screening.
- •- Participants who are either untreated or in the opinion of the Investigator are stable on an allowed disease-modifying therapy (DMT) (interferons, glatiramer acetate, fumarates, or teriflunomide) for at least the past 3 months, and do not require a change in multiple sclerosis (MS) treatment for the duration of Part A and Part B (through Week 96).
- •- Participants with body weight at least 45 kg and body mass index (BMI) at least 18.0 kg/m^2.
- •- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical conditions
- •- Participants with immunodeficiency syndromes or other autoimmune diseases requiring immunosuppressive therapy
- •- Participants with a history of seizures or epilepsy (history of febrile seizure during childhood is allowed).
- •- Participants with known clinical relapse (acute or subacute episodes of new or increasing neurological dysfunction followed by full or partial recovery, in absence of fever or infection) within 8 weeks of study enrollment.
- •- Participants with neurological disease history other than MS, eg, head trauma within 3 months, cerebrovascular disease, and vascular dementia.
- •- Participants with a history of recent serious infection (eg, pneumonia,septicemia) within 4 weeks of screening; an infection requiring hospitalization or intravenous antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infections (such as tuberculosis) deemed unacceptable, as per Investigator’s judgment.
- •- Participants who have significant cognitive impairment, psychiatric disease, other neurodegenerative disorders (eg, Parkinson disease or Alzheimer disease), substance abuse (including a history of alcohol abuse), or any other conditions that would make the
- •participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator.
- •- Participants with a documented history of attempted suicide over the 24 weeks prior to the Screening Visit, presents with suicidal ideation of category 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS),or if in the Investigator's judgment, the participant is at risk for a suicide attempt.
- •- Participants with a history of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than MS precluding their safe participation in this study.
- •- Participants who received a live vaccine within 14 days before the Screening Visit.
- •- Participants with a known history of allergy to any ingredients of SAR443820 (mannitol, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, and microcrystalline cellulose).
- •Prior/concomitant therapy
- •- Participants with a current use of any medications that are moderate or strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4).
- •- Participants with a current use of any of the following medications/treatments: fampridine/dalfampridine, ofatumumab, fingolimod, cladribine, siponimod, ponesimod, ozanimod, alemtuzumab, mitoxantrone, ocrelizumab, natalizumab, or similar approved compounds but with different trade names and any unapproved treatments or therapies for MS; any DMTs newly approved after January 2023 that are marketed at any time during the course of the double-blind study period. These medications are not allowed within 5 half-lives before the Screening Visit and for the duration of Part A and Part B.
- •Prior/concurrent clinical study experience
- •- Participants who have prior/concurrent clinical study enrollment, ie, the participant has taken other investigational drugs within 4 weeks or 5 halflives, whichever is longer, before the first Screening Visit; concurrent or recent participation in non-interventional studies may be permitted.
- •Diagnostic assessments
- •Participants with abnormal laboratory test(s) at t
研究者
相似试验
进行中（未招募）
1 期
Phase 2 study of SAR443820 in participants with multiple sclerosis (MS)Multiple sclerosisEUCTR2022-000049-34-ESSanofi-aventis recherche & développement280
进行中（未招募）
1 期
Phase 2 study of SAR443820 in participants with multiple sclerosis (MS)Multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-000049-34-PLSanofi-aventis recherche & développement280
进行中（未招募）
1 期
Phase 2 study of SAR443820 in participants with multiple sclerosis (MS)Multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-000049-34-DESanofi-aventis recherche & développement280
进行中（未招募）
1 期
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension periodMultiple sclerosisMedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852CTIS2023-509078-45-00Sanofi-Aventis Recherche & Developpement280
已完成
2 期
To study the effect of Under Eye Cream in Healthy Human Volunteers compared to Placebo.CTRI/2012/04/002601Sami labs30